Feb 8, 2017 by Brian Orelli, PhDWhy Cellect Biotechnology Ltd Shares Skyrocketed Higher TodayInvestors are excited about the start of a new clinical trial.
Feb 3, 2017 by Brian Orelli, PhDWhy The Medicines Company Rocketed Higher TodayData from a competitor gives investors hope that the company's drug will have a larger potential market.
Feb 3, 2017 by Brian Orelli, PhDNovo Nordisk A/S Closes the Books on a Tough Year2016 wasn’t kind to the diabetes specialist, and this year doesn't look any easier.
Feb 3, 2017 by Brian Orelli, PhDStrong Fourth Quarter for IDEXX Laboratories, Inc.The maker of animal diagnostic tests rounds out 2016 on a high note.
Feb 3, 2017 by Brian Orelli, PhDWhy Shares of athenahealth, Inc Fell TodayA slowdown in growth has investors a little worried.
Feb 2, 2017 by Brian Orelli, PhDWhy IDEXX Laboratories, Inc. Jumped Higher TodayIt was a nice fourth quarter for the manufacturer of animal instruments and tests.
Feb 2, 2017 by Brian Orelli, PhDQIAGEN NV Continues Its TurnaroundNewer products help boost the top line.
Feb 2, 2017 by Brian Orelli, PhDBaxter International Inc Bumps Its Bottom LineThe turnaround continues as the company spends less and makes more.
Feb 2, 2017 by Brian Orelli, PhDNatus Medical Inc Hears a Bright 2017The neurology and hearing diagnostics expert looks for a solid year with the addition of Otometrics.
Jan 31, 2017 by Brian Orelli, PhDWhy Momenta Pharmaceuticals, Inc. Stock Skyrocketed Higher TodayWinning a patent infringement case moves the drugmaker one step closer to being able to sell its generic version of three-times-weekly Copaxone.
Jan 27, 2017 by Brian Orelli, PhDBiogen Inc Makes Up for Lackluster Revenue GrowthThe biotech turned lackluster revenue growth into a solid increase in earnings by cutting costs.
Jan 27, 2017 by Brian Orelli, PhDCelgene Corporation Continues Its Double-Digit GrowthAnd management's guidance is for more double-digit growth this year.
Jan 26, 2017 by Brian Orelli, PhDMarijuana Stocks: What to Watch in 2017This year could bring DEA scheduling, an FDA approval, and plenty of clinical trial data for some marijuana-based medicines.
Jan 26, 2017 by Brian Orelli, PhDVertex Pharmaceuticals Incorporated Turns a ProfitThe biotech's second cystic fibrosis drug, Orkambi, helps get the company into the black.
Jan 26, 2017 by Brian Orelli, PhD3 Reasons Gilead Sciences Inc. Stock Could RiseThere's hope for this beaten-down biotech, but one of the reasons is out of the company's control.
Jan 19, 2017 by Brian Orelli, PhDGW Pharmaceuticals' Biggest Win in 2016The clear win came from the medical marijuana company's pipeline.
Jan 9, 2017 by Brian Orelli, PhDWhy Exelixis, Inc. Stock Zoomed Higher TodayThe biotech is getting a little bit of cash back from partner Genentech.
Jan 9, 2017 by Brian Orelli, PhDWhy Surgical Care Affiliates Inc Operated Higher TodayA buyout for the health services company sends shares higher.
Jan 5, 2017 by Brian Orelli, PhD5 Slides Every Ionis Pharmaceuticals Inc Investor Needs to SeeA summary of the biotech's pipeline update.
Jan 4, 2017 by Brian Orelli, PhDWhy ImmnoGen, Inc. Jumped Higher TodayThe biotech leaps ahead for no apparent reason.
![img0013[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F432567%2Fimg00131.jpg&w=384&op=resize)
